Crohn's Disease News and Research

Latest Crohn's Disease News and Research

Inflammatory bowel disease in children - Delays in diagnosis common

Once a medical rarity in children, inflammatory bowel disease today is increasingly common in kids, but many of them may not be diagnosed in a timely manner, according to experts from the Pediatric Inflammatory Bowel Disease Center at Johns Hopkins Children’s Center.

28 Mar 2011

Smart Medical to customize NaviAid External Channel Device to suit Crospon's EndoFLIP imaging catheter

Medical device developers, Crospon, based in Ireland and Smart Medical Systems based in Ra'anana, Israel today announced that they have signed a collaborative agreement whereby Smart Medical will produce a custom version of their NaviAid™ external channel endoscope accessory for Crospon, to permit deployment and positioning of Crospon's EndoFLIP™ imaging catheter.

25 Mar 2011

Decision Resources: 68% of gastroenterologists select Remicade for Crohn's treatment

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that more than two-thirds of surveyed gastroenterologists selected Centocor Ortho Biotech/Merck & Co./Mitsubishi Tanabe's Remicade as the most efficacious therapy for Crohn's disease, when compared to other currently available agents.

24 Mar 2011

NephRx receives new U.S. patent for NX002 to treat IBD

NephRx Corporation today announced issuance of a new U.S. patent for use of its novel growth factor peptide NX002 as a potential treatment for inflammatory bowel disease.

24 Mar 2011

NephRx receives new U.S. patent for NX002 to treat oral mucositis

NephRx Corporation today announced issuance of a new U.S. patent for its novel peptide NX002, which currently is in preclinical development for the treatment of oral mucositis.

23 Mar 2011

Gastroenterologist directs new Crohn's and Colitis Program at UT Southwestern

Dorothy Stockstill was taking eight pills a day, and her severe abdominal pain and persistent diarrhea weren't improving. The Denton resident had seen multiple physicians throughout the Dallas area. Her attacks were so severe, she couldn't successfully travel from the front of a retail store to the restrooms in back.

23 Mar 2011

AARDA report on American economic impact of AD released at congressional briefing

A new report by the American Autoimmune Related Diseases Association examining the economic impact of autoimmune disease on Americans, their families and the United States was released today at a congressional briefing as part of AARDA's 2011 National Autoimmune Diseases Awareness Month activities.

23 Mar 2011

Researchers can grow and manipulate personalized gut microbes in laboratory

Each of us carries a unique collection of trillions of friendly microbes in our intestines that helps break down food our bodies otherwise couldn't digest.

22 Mar 2011

Nektar initiates dosing in NKTR-181 Phase 1 clinical study for treatment of pain

Nektar Therapeutics today announced that the first subjects were dosed in a new Phase 1 clinical study to evaluate NKTR-181, the company's next-generation opioid analgesic candidate. NKTR-181 is being developed to effectively treat pain while addressing the abuse liability and serious CNS side effects associated with currently available opioid therapies.

21 Mar 2011

Children and youth with IBD have 25% lower aerobic fitness levels

Children and adolescents growing up with inflammatory bowel disease are less fit than their peers, says a study by researchers at McMaster University and the McMaster Children's Hospital.

17 Mar 2011

Omthera commences dosing in pivotal Epanova Phase III EVOLVE trial in patients with very high triglycerides

Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that the first patient has been dosed in its pivotal Phase III EVOLVE (EpanoVa fOr Lowering Very high triglyceridEs) trial for Epanova™, the Company's lead compound for the treatment of patients with very high triglycerides. Epanova is an Omega-3 fatty acid containing a novel formulation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).

14 Mar 2011

Life Technologies receives FDA 510(k) clearance for StemPro MSC SFM device

Life Technologies Corporation today announced it has received FDA 510(k) clearance for StemPro MSC SFM – a first for this next-generation stem cell culture medium that is now cleared as a medical device and satisfies a crucial requirement for researchers involved in clinical trials in the United States.

14 Mar 2011

Scientists identify regulatory T cells responsible for limiting immune response

Scientists from the Walter and Eliza Hall Institute have identified the key immune cell population responsible for regulating the body's immune response.

6 Mar 2011

Pfizer's ORAL Sync Phase 3 study of tofacitinib in moderate-to-severe RA meets primary endpoints

Pfizer Inc. today announced that the ORAL Sync Phase 3 study of tofacitinib, formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor, being studied in moderate-to-severe rheumatoid arthritis, met its primary endpoints by showing statistically significant changes versus placebo in reducing signs and symptoms of RA, as measured by ACR20 response rates at six months; in improving physical function, as measured by mean change in HAQ DI at three months; and in reaching DAS28-4 <2.6 at six months.

5 Mar 2011

NorthShore receives $1.5 million gift to establish center for the study of complex diseases

NorthShore University HealthSystem (NorthShore) Foundation has received a $1.5 million gift for the creation of the Center for the Study of Complex Diseases. The development of the Center, which is being established within the NorthShore Research Institute, is made possible through a generous gift by Mr. and Mrs. Richard L. Keyser of Glencoe, Ill., through the Keyser Family Research Fund.

4 Mar 2011

New study provides fascinating insight into genetic basis of bipolar disorder

A new study provides fascinating insight into the genetic basis of bipolar disorder, a highly heritable mood disorder characterized by recurrent episodes of mania and depression.

3 Mar 2011

New PSA campaign to raise awareness about autoimmune diseases

The American Autoimmune Related Diseases Association Inc. has unveiled a multi-media public service/awareness campaign titled "We are 50 Million" to herald March 2011 as National Autoimmune Diseases Awareness Month.

2 Mar 2011

SQI Diagnostics first quarter net loss increases to $2,255,000

SQI Diagnostics Inc., a medical systems automation company focused on evolving laboratory-based autoimmune biomarker testing, today announced its financial and operational results for the first quarter ended December 31, 2010.

28 Feb 2011

Final data from 4SC vidofludimus ENTRANCE Phase IIa trial against IBD presented at ECCO IBD Conference

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, announces the final data from the ENTRANCE Phase IIa trial in inflammatory bowel disease with vidofludimus, an oral inhibitor of interleukin-17 release and DHODH, including the secondary endpoints comprising the analysis of CDAI and CAI disease scores, change of prednisolone intake and threshold doses, safety, pharmacokinetics and biomarkers.

28 Feb 2011

Research sheds new light on problem of insulin resistance in type 2 diabetes

A research team, led by La Jolla Institute scientist Joel Linden, Ph.D., has shed new light on the problem of insulin resistance, and identified the key participants in a molecular pathway that holds therapeutic promise for reducing the severity of type 2 diabetes.

25 Feb 2011

Crohn's Disease News and Research

Latest Crohn's Disease News and Research

Inflammatory bowel disease in children - Delays in diagnosis common

Smart Medical to customize NaviAid External Channel Device to suit Crospon's EndoFLIP imaging catheter

Decision Resources: 68% of gastroenterologists select Remicade for Crohn's treatment

NephRx receives new U.S. patent for NX002 to treat IBD

NephRx receives new U.S. patent for NX002 to treat oral mucositis

Gastroenterologist directs new Crohn's and Colitis Program at UT Southwestern

AARDA report on American economic impact of AD released at congressional briefing

Researchers can grow and manipulate personalized gut microbes in laboratory

Nektar initiates dosing in NKTR-181 Phase 1 clinical study for treatment of pain

Children and youth with IBD have 25% lower aerobic fitness levels

Omthera commences dosing in pivotal Epanova Phase III EVOLVE trial in patients with very high triglycerides

Life Technologies receives FDA 510(k) clearance for StemPro MSC SFM device

Scientists identify regulatory T cells responsible for limiting immune response

Pfizer's ORAL Sync Phase 3 study of tofacitinib in moderate-to-severe RA meets primary endpoints

NorthShore receives $1.5 million gift to establish center for the study of complex diseases

New study provides fascinating insight into genetic basis of bipolar disorder

New PSA campaign to raise awareness about autoimmune diseases

SQI Diagnostics first quarter net loss increases to $2,255,000

Final data from 4SC vidofludimus ENTRANCE Phase IIa trial against IBD presented at ECCO IBD Conference

Research sheds new light on problem of insulin resistance in type 2 diabetes

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Crohn's Disease News and Research

Latest Crohn's Disease News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in